Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
Internal Medicine Journal
|
April 2, 2025
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma
Michael Dickinson, Nicole O'Leary, Nada Hamad, et al.
British Journal of Haematology
|
April 18, 2024
Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study
Cameron S Lewis, Greta Joy, Paw Jensen, et al.
Blood Advances
|
January 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study
Allison Barraclough, Sze Ting Lee, Melinda Burgess, et al.
Blood Advances
|
January 18, 2025
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review
Luke Wang, Eliza Chung, Cameron Wellard, et al.
Haematologica
|
September 25, 2025
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study
Eliza Chung, Luke Wang, Cameron Wellard, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
June 24, 2026
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study
Gemma K Reynolds, Mark R Dowling, Safia Belbachir, et al.
Leukemia
|
March 11, 2023
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study
Kate Manos, Geoffrey Chong, Colm Keane, et al.
Journal of the National Cancer Institute
|
July 10, 2025
Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival
Kimberly S Q Wong, Arina Martynchyk, Zoe Krisnadi, et al.
Blood Advances
|
June 20, 2025
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trial
Eliza A Hawkes, Jodie Palmer, Richard Khor, et al.
Ejhaem
|
April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project
Briony Shaw, Eliza Chung, Cameron Wellard, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
Internal Medicine Journal
|
April 2, 2025
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma
Michael Dickinson, Nicole O'Leary, Nada Hamad, et al.
British Journal of Haematology
|
April 18, 2024
Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study
Cameron S Lewis, Greta Joy, Paw Jensen, et al.
Blood Advances
|
January 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study
Allison Barraclough, Sze Ting Lee, Melinda Burgess, et al.
Blood Advances
|
January 18, 2025
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review
Luke Wang, Eliza Chung, Cameron Wellard, et al.
Haematologica
|
September 25, 2025
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study
Eliza Chung, Luke Wang, Cameron Wellard, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
June 24, 2026
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study
Gemma K Reynolds, Mark R Dowling, Safia Belbachir, et al.
Leukemia
|
March 11, 2023
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study
Kate Manos, Geoffrey Chong, Colm Keane, et al.
Journal of the National Cancer Institute
|
July 10, 2025
Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival
Kimberly S Q Wong, Arina Martynchyk, Zoe Krisnadi, et al.
Blood Advances
|
June 20, 2025
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trial
Eliza A Hawkes, Jodie Palmer, Richard Khor, et al.
Ejhaem
|
April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project
Briony Shaw, Eliza Chung, Cameron Wellard, et al.
Page
of 3